Apr. 4, 2023
FTC blocks Illumina’s purchase of cancer biotech
The agency’s decision is a victory for the more aggressive approach to antitrust enforcement it has taken under FTC Chair Lina M. Khan.
The U.S. Federal Trade Commission overruled its own administrative law judge and ordered San Diego biotechnology company Illumina Inc. to divest Grail Inc., a company devoted to the early detection of cancer.
Illumina in a statement Monday said it “intends to file a petition for review promptly with a U.S. Court of Appeals and will seek expedited treatment of the appeal. The FTC’s order to unwind the acquisition will be automatically staye...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In